Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms

Clinical Infectious Diseases

Volumn 46, Issue 11, 2008, Pages 1683-1693

  Stryjewski, Martin E ^a,h,j   Graham, Donald R ^b   Wilson, Samuel E ^c   O'Riordan, William ^d   Young, David ^e   Lentnek, Arnold ^g   Ross, Douglas P ⁱ   Fowler, Vance G ^a   Hopkins, Alan ^f   Friedland, H David ^f   Barriere, Steven L ^f   Kitt, Michael M ^f   Corey, G Ralph ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Springfield Clinic   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Study Site   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f THERAVANCE INC   (United States)

^g WellStar Health System   (United States)

^h CEMIC   (Argentina)

ⁱ St Mary's Hospital   (South Africa)

^j NONE   (Argentina)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; METRONIDAZOLE; TELAVANCIN; VANCOMYCIN;

ABDOMINAL PAIN; ADULT; AGED; ANXIETY DISORDER; ARTICLE; CHILL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DECREASED APPETITE; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EOSINOPHILIA; FATIGUE; FEMALE; GRAM POSITIVE BACTERIUM; HEADACHE; HEMATOCRIT; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INSOMNIA; KIDNEY DISEASE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NAUSEA; NONHUMAN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SKIN INFECTION; SKIN STRUCTURE; STAPHYLOCOCCUS INFECTION; SURGICAL DRAINAGE; TASTE DISORDER; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URINE; VOMITING;

ADULT; AMINOGLYCOSIDES; DOUBLE-BLIND METHOD; FEMALE; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; SKIN DISEASES, INFECTIOUS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 43949095864     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/587896     Document Type: Article

References (31)

1. Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis 2001; 7:178-82.
2. Deresinski S. Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. Clin Infect Dis 2005; 40:562-73.
3. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32:470-85.
4. World Health Organization (WHO); EMERGEncy ID Net Study Group. Overcoming antimicrobial resistance: world health report on infectious diseases 2000: a message from the Director-General, World Health Organization. Available at: http://www.who.int/infectiousdisease-report/2000/other_versions/ index-rpt2000_text.html. Accessed 12 December 2006.
5. Grundmann H, Aires-de-Sousa M, Boyce J, Tiemersma E. Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a publichealth threat. Lancet 2006; 368:874-85.
6. Herold BC, Immergluck LC, Maranan MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998; 279:593-8.
7. Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus - Minnesota and North Dakota, 1997-1999. JAMA 1999; 282:1123-5.
8. Naimi TS, LeDell KH, Boxrud DJ, et al. Epidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996-1998. Clin Infect Dis 2001; 33:990-6.
9. Kazakova SV, Hageman JC, Matava M, et al. A clone of methicillin- resistant Staphylococcus aureus among professional football players. N Engl J Med 2005; 352:468-75.
10. King MD, Humphrey BJ, Wang YF, Kourbatova EV, Ray SM, Blumberg HM. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med 2006; 144:309-17.
11. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355:666-74.
12. Crum NF, Lee RU, Thornton SA, et al. Fifteen-year study of the changing epidemiology of methicillin-resistant Staphylococcus aureus. Am J Med 2006; 119:943-51.
13. Seybold U, Kourbatova EV, Johnson JG, et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin Infect Dis 2006; 42:647-56.
14. Klevens RM, Edwards JR, Tenover FC, McDonald LC, Horan T, Gaynes R; National Nosocomial Infections Surveillance System. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. Clin Infect Dis 2006; 42:389-91.
15. Gonzalez BE, Rueda AM, Shelburne SA 3rd, Musher DM, Hamill RJ, Hulten KG. Community-associated strains of methicillin-resistant Staphylococccus aureus as the cause of healthcare-associated infection. Infect Control Hosp Epidemiol 2006; 27:1051-6.
16. Liu C, Chambers HF. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother 2003; 47:3040-5.
17. Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:565-7.
18. Centers for Disease Control and Prevention. Vancomycin-resistant Staphylococcus aureus - Pennsylvania, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:902 (erratum: MMWR Morb Mortal Wkly Rep 2002; 51:931).
19. Higgins DL, Chang R, Debabov DV, et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49:1127-34.
20. Pace JL, Krause K, Johnston D, et al. In vitro activity of TD-6424 against Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47:3602-4.
21. King A, Phillips I, Kaniga K. Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against gram-positive bacteria. J Antimicrob Chemother 2004; 53:797-803.
22. Leuthner KD, Cheung CM, Rybak MJ. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006; 58:338-43.
23. Shaw JP, Seroogy J, Kaniga K, Higgins DL, Kitt M, Barriere S. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother 2005; 49:195-201.
24. Koch GG, Carr GJ, Amara IA, Stokes ME, Uryniak TJ. Categorical data analysis. In: Berry DA, ed. Statistical methodology in pharmaceutical sciences. New York: Marcel Dekker, 1990:291-475.
25. Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005; 49:2260-6.
26. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI; Daptomycin 98-01 and 99-01 Investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38:1673-81.
27. Nichols RL, Graham DR, Barriere SL, et al. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. J Antimicrob Chemother 1999; 44:263-73.
28. Cohen PR. Community-acquired methicillin-resistant Staphyloccocus aureus skin infections: a review of epidemiology, clinical features, management, and prevention. Int J Dermatol 2007; 46:1-11.
29. Stryjewski ME, O'Riordan WD, Lau WK, et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis 2005; 40:1601-7.
30. Stryjewski ME, Chu VH, O'Riordan WD, et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother 2006; 50:862-7.
31. McKinnon PS, Sorensen SV, Liu LZ, Itani KM. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections. Ann Pharmacother 2006; 40:1017-23.